Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat (NASDAQ:OCUL)
· seekingalpha.com
Ocular Therapeutix eyes a 2027 AXPAXLI launch for wet AMD/retinal disease with strong Phase 3 data, an FDA-aligned NDA in Q4 2026. Click here to read more.
My bullish view on Ocular Therapeutix ( OCUL ) is not just based on AXPAXLI becoming another long-duration treatment for wet AMD. I think AXPAXLI could also bec...